Last reviewed · How we verify
ZIEXTENZO (PEGFILGRASTIM-BMEZ)
ZIEXTENZO (generic name: PEGFILGRASTIM-BMEZ) is a Leukocyte Growth Factor [EPC] drug developed by SANDOZ INC. It is currently FDA-approved.
At a glance
| Generic name | PEGFILGRASTIM-BMEZ |
|---|---|
| Sponsor | SANDOZ INC |
| Drug class | Leukocyte Growth Factor [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Bone pain
- Pain in extremity
Serious adverse events
- Splenic Rupture
- Leukocytosis (WBC counts > 100 x 10^9/L)
Key clinical trials
- Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Ly (Phase 2)
- A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage I (Phase 2)
- Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell Lymphomas (Phase 1)
- A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (Phase 2)
- Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Lar (Phase 1)
- A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular (Phase 1)
- Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Po (Phase 2)
- A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZIEXTENZO CI brief — competitive landscape report
- ZIEXTENZO updates RSS · CI watch RSS
- SANDOZ INC portfolio CI
Frequently asked questions about ZIEXTENZO
What is ZIEXTENZO?
ZIEXTENZO (PEGFILGRASTIM-BMEZ) is a Leukocyte Growth Factor [EPC] drug developed by SANDOZ INC.
Who makes ZIEXTENZO?
ZIEXTENZO is developed and marketed by SANDOZ INC (see full SANDOZ INC pipeline at /company/sandoz).
What is the generic name of ZIEXTENZO?
PEGFILGRASTIM-BMEZ is the generic (nonproprietary) name of ZIEXTENZO.
What drug class is ZIEXTENZO in?
ZIEXTENZO belongs to the Leukocyte Growth Factor [EPC] class. See all Leukocyte Growth Factor [EPC] drugs at /class/leukocyte-growth-factor-epc.
What development phase is ZIEXTENZO in?
ZIEXTENZO is FDA-approved (marketed).
What are the side effects of ZIEXTENZO?
Common side effects of ZIEXTENZO include Bone pain, Pain in extremity. Serious adverse events: Splenic Rupture, Leukocytosis (WBC counts > 100 x 10^9/L).
Related
- Drug class: All Leukocyte Growth Factor [EPC] drugs
- Manufacturer: SANDOZ INC — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing